LM-168

Phase 2Small molecule

LLaNova Medicines Limited

LM-168 is one of 47 small molecule programs targeting Solid Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

Advanced Solid TumoursRecruiting

Solid TumorPhase 2

Recruiting

Advanced Solid TumoursPhase 2

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

Nubeqa

Bayer

Preclinical

2 3

Fludara

Sanofi

Preclinical

1 4

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 5

LM-168

LLaNova Medicines Limited

Phase 2

1 6

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 7

Navmi

SSummit Therapeutics

Preclinical

1 8

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 9

Tulmimetostat

Novartis

Preclinical

1 10

Carboplatin AUC-5

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Recruiting

Advanced Solid Tumours

NCT06868199

Q4 2028

Phase 2Recruiting

Solid Tumor

NCT07669415

Clinical

Trials by Indication[1]

Advanced Solid Tumours1 trial

A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Recruiting·LLaNova Medicines Limited·Phase 1/2·NCT06868199·87 enrolled

Solid Tumor1 trial

A Phase II，Open Label,Multicenter Study to Evaluate the Efficacy,Safety,and Tolerability of LM-168 Combined With Other Anti-tumor Therapies in Participants With Advanced Solid Tumor Trials

Recruiting·LLaNova Medicines Limited·Phase 2·NCT07669415·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for LM-168. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LM-168 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LM-168. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LaNova Medicines Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLaNova Medicines Limited

LM-168

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2028

Trials by Indication[1]

Advanced Solid Tumours1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News